We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reconstituted HDL-siRNA Nanoparticles Block Cancer Growth in Mouse Models

By LabMedica International staff writers
Posted on 12 Apr 2011
Print article
Synthetic HDL (high-density lipoprotein) nanoparticles loaded with small interfering RNA (siRNA) have been used to inhibit growth of tumor cells in mouse models of ovarian and colorectal cancer.

Investigators at the University of Texas MD Anderson Cancer Center (Houston, USA) have been seeking an effective and nontoxic means for introducing gene-silencing miRNA into cancer cells. In this study, they exploited the need for cancer cells to take up large quantities of HDL through the SR-B1 receptor, which is overexpressed by many types of tumors. The only normal cells expressing this receptor are in the liver.

The investigators reported in the April 2011 issue of the journal Neoplasia that they had succeeded in establishing a novel formulation of siRNA by incorporating it into reconstituted high-density lipoprotein (rHDL) nanoparticles. They demonstrated that rHDL nanoparticles facilitated highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1 receptor. These nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 [STAT3] and focal adhesion kinase [FAK]) in mouse models of ovarian and colorectal cancer.

"RNA interference has great therapeutic potential but delivering it to cancer cells has been problematic,” said senior author Dr. Anil Sood, professor of cancer biology at the MD Anderson Cancer Center. "Combining siRNA with HDL provides an efficient way to get these molecules to their targets. If siRNA is not in a nanoparticle, it gets broken down and excreted before it can be effective. HDL is completely biocompatible and is a safety improvement over other types of nanoparticles. This study has several important implications in the ability to fight certain cancers.”

"In order to help expedite the study's progress to a clinical setting, we have identified 12 genes as biomarkers for response to STAT3-targeted therapy,” said Dr. Sood. ”Next, we will work with the [US] National Cancer Institute Nanoparticle Characterization Lab (Frederick, MD, USA) to develop a formulation of the HDL/siRNA nanoparticle for human use.”

Related Links:
University of Texas MD Anderson Cancer Center
National Cancer Institute Nanoparticle Characterization Lab


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.